{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T20:32:55Z","timestamp":1762374775729},"reference-count":21,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2003,5,9]],"date-time":"2003-05-09T00:00:00Z","timestamp":1052438400000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Geriat Psychiatry"],"published-print":{"date-parts":[[2003,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Ischaemic vascular dementia shares risk factors with stroke. There is evidence that control of these risk factors may prevent or alter the course of vascular dementia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess the effect of regular low\u2010dose aspirin on outcomes for patients with vascular dementia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Retrospective analysis of hospital case\u2010notes with further outcome information from telephone calls to general practitioners, social services and institutions. Comparison of outcomes for aspirin\u2010treated and untreated patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>One North London NHS Trust.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients<\/jats:title><jats:p>Seventy\u2010eight patients with clinician's diagnosis of ischaemic vascular dementia, discharged from acute inpatient units between 1 January 1995 and 31 December 1997; 38 on aspirin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main outcome measures<\/jats:title><jats:p>Survival times from dementia onset to institutionalization and death.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Median survival time to institutionalization was 28 months and to death was 52 months. There was no overall difference between aspirin and non\u2010aspirin groups for these outcomes. When data were stratified for social status, i.e. living alone or with carer when last at home, differences emerged for those living with carer. Aspirin was associated with a trend towards increased time to institutionalization (39 <jats:italic>vs<\/jats:italic> 22 months, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.09) and a significant advantage in time to death (71 <jats:italic>vs<\/jats:italic> 27 months, <jats:italic>p<\/jats:italic>\u2009=\u20090.02). These effects were non\u2010significant after statistical adjustment for confounding variables.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The results support but do not prove a role for regular, low\u2010dose aspirin in improving both life expectancy and survival at home for patients with vascular dementia. Compliance may be better in those living with a carer. Larger, prospective studies should be performed to confirm these findings. Cognitive and behavioural outcomes should also be studied. Copyright \u00a9 2003 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/gps.857","type":"journal-article","created":{"date-parts":[[2003,5,21]],"date-time":"2003-05-21T10:00:48Z","timestamp":1053511248000},"page":"425-431","source":"Crossref","is-referenced-by-count":19,"title":["Does aspirin affect outcome in vascular dementia? A retrospective case\u2010notes analysis"],"prefix":"10.1002","volume":"18","author":[{"given":"M. E.","family":"Devine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Rands","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,5,9]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7329.71"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.177.1.66"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1192\/pb.22.5.285"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)03086-4"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-4580(00)00241-4"},{"issue":"45","key":"e_1_2_1_7_1","first-page":"2223","article-title":"Multi\u2010infarct dementia in nursing home patients; more comorbidity and shorter life expectancy than in Alzheimer's disease","volume":"136","author":"Koopmans RT","year":"1992","journal-title":"Ned Tijdschr Geneeskd"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1159\/000110921"},{"issue":"16","key":"e_1_2_1_9_1","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1001\/jama.1986.03380160061021","article-title":"Improved cognition after control of risk factors for multi\u2010infarct dementia","volume":"256","author":"Meyer JS","year":"1986","journal-title":"JAMA"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1989.tb05688.x"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-4580(00)00136-6"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1986.tb04634.x"},{"key":"e_1_2_1_13_1","unstructured":"National Institute for Clinical Excellence.2001.Guidance on the Use of Donepezil Rivastigmine and Galantamine for the Treatment of Alzheimer's Disease. NICE Technology Appraisal Guidance\u2014No. 19."},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03589-3"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.28.2.316"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.9.1937"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004150050021"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)90608-X"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1159\/000026147"},{"key":"e_1_2_1_20_1","volume-title":"The Cochrane Library, Issue 1","author":"Williams PS","year":"2003"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104123441501"},{"key":"e_1_2_1_22_1","volume-title":"The ICD\u201010 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines","author":"World Health Organization","year":"1992"}],"container-title":["International Journal of Geriatric Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fgps.857","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/gps.857","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T19:53:19Z","timestamp":1700250799000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/gps.857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2003,5]]}},"alternative-id":["10.1002\/gps.857"],"URL":"https:\/\/doi.org\/10.1002\/gps.857","archive":["Portico"],"relation":{},"ISSN":["0885-6230","1099-1166"],"issn-type":[{"value":"0885-6230","type":"print"},{"value":"1099-1166","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,5]]}}}